Ph.D. Program in Clinical Drug Development of Herbal Medicine, College of Pharmacy, Taipei Medical University, Taipei, 11031, Taiwan; National Research Institute of Chinese Medicine, Taipei, 11221, Taiwan.
National Research Institute of Chinese Medicine, Taipei, 11221, Taiwan; Department of Marine Biotechnology and Resources, National Sun Yat-sen University, Kaohsiung, 80424, Taiwan.
Phytochemistry. 2021 Apr;184:112666. doi: 10.1016/j.phytochem.2021.112666. Epub 2021 Jan 29.
After anti-angiogenic activity screening, the potential n-butanol layer partitioned from the ethanol extract of Staurogyne concinnula was conducted. Further purification by Diaion HP20 column and preparative HPLC chromatography, four undescribed triterpenoid saponin derivatives, along with the known baptisiasaponin I, and four known phenylpropanoid glycosides were isolated and characterized from n-butanol layer. The structures of isolated compounds were elucidated by ESI-MS, 1D, and 2D MNR data. Biological evaluation revealed that baptisiasaponin I possessed significant anti-angiogenic effects (IC 4.0 ± 0.2 μM). Further mechanism of action of baptisiasaponin I by inhibition of integrin/FAK/paxillin signaling pathway and its downstream effectors as MMP2 and MMP9 are also presented.
经抗血管生成活性筛选，从星宿菜乙醇提取物的正丁醇层中进行分离。通过 Diaion HP20 柱和制备 HPLC 色谱进一步纯化，从正丁醇层中分离并鉴定出四种未知的三萜皂苷衍生物，以及已知的荭草皂苷 I 和四种已知的苯丙素糖苷。通过 ESI-MS、1D 和 2D MNR 数据阐明了分离化合物的结构。生物评价表明，荭草皂苷 I 具有显著的抗血管生成作用（IC 4.0±0.2 μM）。还呈现了荭草皂苷 I 通过抑制整合素/FAK/桩蛋白信号通路及其下游效应物 MMP2 和 MMP9 的作用机制。
